Who is sponsoring NCT00296855?

NCT00296855 is sponsored by Bayer.

What condition does NCT00296855 study?

NCT00296855 studies Peripheral Vascular Diseases.

What drugs are being tested in NCT00296855?

Interventions: Vasovist (BAY86-5283, MS-325).

What is the status of NCT00296855?

NCT00296855 is currently COMPLETED.

Last reviewed 2010-04-22 · How we verify

Intra-individual Open-label Multicenter Comparison Study of Magnetic Resonance Angiography (MRA) With the Blood Pool Contrast Agent Vasovist® and a Conventional Extracellular Contrast Agent With Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients With Peripheral Artery Disease

NCT00296855 Phase 3 COMPLETED

The particular aim of this study is the comparison of the diagnostic results of MRA images upon application of Vasovist (gadofosveset), a contrast agent not yet available on the market, with the MRA images upon application of a conventional extracellular contrast agent. A catheter angiography, which will be performed as a routine diagnostic procedure for vascular diseases, will serve as an evaluation standard.

Details

Lead sponsor	Bayer
Phase	Phase 3
Status	COMPLETED
Enrolment	261
Start date	2006-02
Completion	2007-02

Conditions

Peripheral Vascular Diseases

Interventions

Vasovist (BAY86-5283, MS-325)

Primary outcomes

Diagnostic potential of Vasovist enhanced MRA — Imaging after baseline visit, before and after Vasovist injection

Countries

Argentina, Austria, Brazil, Germany, Mexico, Switzerland